References
- Sakula A. BCG: who were Calmette and Guérin? Thorax. 1983;38(11):806–812. Available from: https://thorax.bmj.com/content/thoraxjnl/38/11/806.full.pdf
- Calmette A. Preventive vaccination against tuberculosis with BCG. Proc R Soc Med. [internet]. 1931;24:1481–1490. Available from: https://pubmed.ncbi.nlm.nih.gov/19988326
- Toida I. Development of the mycobacterium bovis BCG vaccine: review of the historical and biochemical evidence for a genealogical tree. Tuber Lung Dis. 2000;80:291.
- Office WHOTR, Campaign IT Mass BCG vaccination campaigns: 1948-1951/reports prepared by the tuberculosis research office, World Health Organization [internet]. Copenhagen: International Tuberculosis Campaign; Available from: https://apps.who.int/iris/handle/10665/62743
- WHO Expert Committee on biological standardization [meeting held in Geneva from 28 November to 3 December 1966]: nineteenth report [internet]; 1967. Available from: https://apps.who.int/iris/handle/10665/40655
- Lugosi L, Jacobs WR, Bloom BR, Genetic transformation of BCG. Tubercle. [internet]. 1989; 70(3):159–170. Available from: http://europepmc.org/abstract/MED/2694552
- Mahairas GG, Sabo PJ, Hickey MJ, et al. Molecular analysis of genetic differences between mycobacterium bovis BCG and virulent M. bovis. J Bacteriol. [internet]. 1996; 178(5):1274–1282. Available from: https://pubmed.ncbi.nlm.nih.gov/8631702
- Kleinnijenhuis J, Quintin J, Preijers F, et al. Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci U S A. 2012;109(43):17537–17542.
- Arbues A, Aguilo JI, Gonzalo-Asensio J, et al. Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials. Vaccine. [internet]. 2013;31(42):4867–4873. Available from: http://www.sciencedirect.com/science/article/pii/S0264410X13010086
- Choudhary E, Thakur P, Pareek M, et al. Gene silencing by CRISPR interference in mycobacteria. Nat Commun. 2015/02/26. 2015;6(1):6267.
- Harding E, WHO global progress report on tuberculosis elimination. Lancet Respir Med [internet]. 2019/11/11. 2020;8(1):19. Available from: https://www.ncbi.nlm.nih.gov/pubmed/31706931
- Andersen P, Scriba TJ, Moving tuberculosis vaccines from theory to practice. Nat Rev Immunol. [internet]. 2019;19(9):550–562. Available from: https://doi.org/10.1038/s41577-019-0174-z
- Ogongo P, Porterfield JZ, Leslie A. Lung tissue resident memory T-cells in the immune response to mycobacterium tuberculosis [internet]. Front Immunol. 2019;10:992.
- Hu Z, Zhao H-M, Li C-L, et al. The role of KLRG1 in human CD4+ T-cell immunity against tuberculosis. J Infect Dis. [internet]. 2018;217(9):1491–1503. Available from: https://doi.org/10.1093/infdis/jiy046
- Abadie V, Badell E, Douillard P, et al. Neutrophils rapidly migrate via lymphatics after mycobacterium bovis BCG intradermal vaccination and shuttle live bacilli to the draining lymph nodes. Blood [internet]. 2005/05/12. 2005;106(5):1843–1850. Available from: https://www.ncbi.nlm.nih.gov/pubmed/15886329
- Sugisaki K, Dannenberg Jr AM, Abe Y, et al. Nonspecific and immune-specific up-regulation of cytokines in rabbit dermal tuberculous (BCG) lesions. J Leukoc Biol [internet]. 1998/04/17. 1998;63(4):440–450. Available from: https://www.ncbi.nlm.nih.gov/pubmed/9544573
- Lalor MK, Floyd S, Gorak-Stolinska P, et al. BCG vaccination induces different cytokine profiles following infant BCG vaccination in the UK and Malawi. J Infect Dis. 2011/09/02. 2011;204(7):1075–1085.
- Tanner R, Villarreal-Ramos B, Vordermeier HM, et al. The humoral immune response to BCG vaccination. Front Immunol. 2019/06/28 2019;10: 1317.
- Netea MG, Quintin J, van der Meer JWM, Trained immunity: a memory for innate host defense. Cell Host Microbe. [internet]. 2011;9(5):355–361. Available from: https://doi.org/10.1016/j.chom.2011.04.006
- Netea MG, Joosten LA, Latz E, et al. Trained immunity: a program of innate immune memory in health and disease. Science. 2016/04/23. 2016;352(6284):aaf1098.
- Escobar LE, Molina-Cruz A, Barillas-Mury C, BCG vaccine protection from severe coronavirus disease 2019 (COVID-19). Proc Natl Acad Sci. [internet]. 2020;117(30):17720. Available from: http://www.pnas.org/content/117/30/17720.abstract
- Angelidou A, Conti M-G, Diray-Arce J, et al. Licensed Bacille Calmette-Guérin (BCG) formulations differ markedly in bacterial viability, RNA content and innate immune activation. Vaccine. [internet]. 2020;38(9):2229–2240. Available from: https://www.sciencedirect.com/science/article/pii/S0264410X19316147
- Stover CK, De La Cruz VF, Fuerst TR, et al. New use of BCG for recombinant vaccines. Nature. [internet]. 1991;351(6326):456–460. Available from: https://doi.org/10.1038/351456a0
- Oliveira TL, Rizzi C, Dellagostin OA. Recombinant BCG vaccines: molecular features and their influence in the expression of foreign genes. Appl Microbiol Biotechnol. 2017/08/06. 2017;101(18):6865–6877.
- Matsumoto S, Matsuo T, Ohara N, et al. Cloning and sequencing of a unique antigen MPT70 from mycobacterium tuberculosis H37Rv and expression in BCG using E. coli-mycobacteria shuttle vector. Scand J Immunol. [internet]. 1995;41(3):281–287. Available from: https://doi.org/10.1111/j.1365-3083.1995.tb03565.x
- Borsuk S, Mendum TA, Fagundes MQ, et al. Auxotrophic complementation as a selectable marker for stable expression of foreign antigens in mycobacterium bovis BCG. Tuberc. 2007/09/25. 2007;87(6):474–480.
- Nascimento IP, Dias WO, Quintilio W, et al. Construction of an unmarked recombinant BCG expressing a pertussis antigen by auxotrophic complementation: protection against Bordetella pertussis challenge in neonates. Vaccine. [internet]. 2009;27(52):7346–7351. Available from: http://www.sciencedirect.com/science/article/pii/S0264410X09013772
- Miyaji EN, Mazzantini RP, Dias WO, et al. Induction of neutralizing antibodies against diphtheria toxin by priming with recombinant mycobacterium bovis BCG expressing CRM 197, a mutant diphtheria toxin. Infect Immun. 2001/02/13. 2001;69(2):869–874.
- Kanno AI, Goulart C, Rofatto HK, et al. New recombinant mycobacterium bovis BCG expression vectors: improving genetic control over mycobacterial promoters. Appl Environ Microbiol. 2016;82(8):2240–2246. Available from: https://aem.asm.org/content/aem/82/8/2240.full.pdf
- DasGupta SK, Jain S, Kaushal D, et al. Expression systems for study of mycobacterial gene regulation and development of recombinant BCG vaccines. Biochem Biophys Res Commun. [1998 Jun 10]. 1998;246(3):797–804.
- Gormley E, Sandall L, Hong C, et al. Identification and differentiation of mycobacteria using the PAN promoter sequence from mycobacterium paratuberculosis as a DNA probe. FEMS Microbiol Lett. [1997 Feb 01]. 1997;147:63–68.
- Varaldo PB, Miyaji EN, Vilar MM, et al. Mycobacterial codon optimization of the gene encoding the Sm14 antigen of Schistosoma mansoni in recombinant mycobacterium bovis bacille Calmette-Guérin enhances protein expression but not protection against cercarial challenge in mice. FEMS Immunol Med Microbiol. [internet]. 2006;48(1):132–139. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16965361
- Méderlé I, Bourguin I, Ensergueix D, et al. Plasmidic versus insertional cloning of heterologous genes in mycobacterium bovis BCG: impact on in vivo antigen persistence and immune responses. Infect Immun. 2001/ 12/19. 2002;70(1):303–314.
- Murray PJ, Aldovini A, Young RA. Manipulation and potentiation of antimycobacterial immunity using recombinant bacille Calmette-Guérin strains that secrete cytokines. Proc Natl Acad Sci U S A [internet]. 1996;33:934–939. Available from: https://pubmed.ncbi.nlm.nih.gov/8570663
- Ehrt S, Guo XV, Hickey CM, et al. Controlling gene expression in mycobacteria with anhydrotetracycline and Tet repressor. Nucleic Acids Res. 2005/02/03. 2005;33(2):e21.
- Oliveira TL, Stedman A, Rizzi C, et al. A standardized BioBrick toolbox for the assembly of sequences in mycobacteria. Tuberculosis [internet]. 2019;119:101851. Available from: https://www.sciencedirect.com/science/article/pii/S1472979219301374
- Bardarov S, Bardarov S, Pavelka MS, et al. Specialized transduction: an efficient method for generating marked and unmarked targeted gene disruptions in mycobacterium tuberculosis, M. bovis BCG and M. smegmatis. Microbiology. 2002/10/09. 2002;148(10):3007–3017.
- Balasubramanian V, Pavelka Jr MS, Bardarov SS, et al. Allelic exchange in mycobacterium tuberculosis with long linear recombination substrates. J Bacteriol. [internet]. 1996;178(1):273–279. Available from: https://pubmed.ncbi.nlm.nih.gov/8550428
- Singh AK, Carette X, Potluri L-P, et al. Investigating essential gene function in mycobacterium tuberculosis using an efficient CRISPR interference system. Nucleic Acids Res [internet]. 2016/07/12. 2016;44(18):e143–e143. Available from: https://pubmed.ncbi.nlm.nih.gov/27407107
- Yan MY, Li SS, Ding XY, et al. A CRISPR-assisted nonhomologous end-joining strategy for efficient genome editing in mycobacterium tuberculosis. MBio. 2020/01/30. 2020;11(1). doi:https://doi.org/10.1128/mBio.02364-19.
- Zetsche B, Gootenberg JS, Abudayyeh OO, et al. Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. Cell. 2015/10/01. 2015;163(3):759–771.
- Meijers AS, Troost R, Ummels R, et al. Efficient genome editing in pathogenic mycobacteria using Streptococcus thermophilus CRISPR1-Cas9. Tuberculosis [internet]. 2020;124:101983. Available from: http://www.sciencedirect.com/science/article/pii/S1472979220301505
- Huygen K. The Immunodominant T-cell epitopes of the mycolyl-transferases of the antigen 85 complex of M. tuberculosis. Front Immunol [internet]. 2014;5:321. Available from: https://pubmed.ncbi.nlm.nih.gov/25071781
- Zhang W, Zhang Y, Zheng H, et al. Genome sequencing and analysis of BCG vaccine strains. PLoS One. 2013/08/27. 2013;8(8):e71243.
- Gröschel MI, Sayes F, Shin SJ, et al. Recombinant BCG expressing ESX-1 of mycobacterium marinum combines low virulence with cytosolic immune signaling and improved TB protection. Cell Rep. [internet]. 2017;18(11):2752–2765. Available from: http://www.sciencedirect.com/science/article/pii/S2211124717302553
- Yousefi Avarvand A, Khademi F, Tafaghodi M, et al. The roles of latency-associated antigens in tuberculosis vaccines. Indian J Tuberc. [internet]. 2019;66(4):487–491. Available from: http://www.sciencedirect.com/science/article/pii/S001957071630381X
- Gillis TP, Tullius MV, Horwitz MA. rBCG30-induced immunity and cross-protection against mycobacterium leprae challenge are enhanced by boosting with the mycobacterium tuberculosis 30-kilodalton antigen 85B. Infect Immun. 2014/07/09. 2014;82(9):3900–3909.
- Ahn SK, Tran V, Leung A, et al. Recombinant BCG overexpressing phoP-phoR confers enhanced protection against tuberculosis. Mol Ther. 2018/10/03. 2018;26(12):2863–2874.
- Solans L, Gonzalo-Asensio J, Sala C, et al. The PhoP-dependent ncRNA Mcr7 modulates the TAT secretion system in mycobacterium tuberculosis. PLOS Pathog. [internet]. 2014;10(5):e1004183. Available from: https://doi.org/10.1371/journal.ppat.1004183
- White AD, Sibley L, Sarfas C, et al. MTBVAC vaccination protects rhesus macaques against aerosol challenge with M. tuberculosis and induces immune signatures analogous to those observed in clinical studies. Vaccines (Basel) [internet]. 2021;6:4. Available from: https://doi.org/10.1038/s41541-020-00262-
- Tameris M, Mearns H, Penn-Nicholson A, et al. Live-attenuated mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial. Lancet Respir Med. 2019/08/17. 2019;7(9):757–770.
- Mizuno S, Soma S, Inada H, et al. SOCS1 antagonist–expressing recombinant bacillus Calmette–Guérin enhances antituberculosis protection in a mouse model. J Immunol. 2019;ji1800694. Available from: https://www.jimmunol.org/content/jimmunol/early/2019/05/16/jimmunol.1800694.full.pdf
- Nascimento IP, Rodriguez D, Santos CC, et al. Recombinant BCG expressing LTAK63 adjuvant induces superior protection against mycobacterium tuberculosis. Sci Rep. [internet]. 2017;7(1):2109. Available from: https://doi.org/10.1038/s41598-017-02003-9
- Carvalho Dos Santos C, Rodriguez D, Kanno IA, et al. Recombinant BCG expressing the LTAK63 adjuvant induces increased early and long-term immune responses against mycobacteria. Hum Vaccin Immunother. 2019/ 11/02. 2020;16(3):673–683.
- Desel C, Dorhoi A, Bandermann S, et al. Recombinant BCG ΔureC hly+ induces superior protection over parental BCG by stimulating a balanced combination of type 1 and type 17 cytokine responses. J Infect Dis [internet]. 2011/09/20. 2011; 204(10):1573–1584. Available from: https://pubmed.ncbi.nlm.nih.gov/21933877
- Grode L, Seiler P, Baumann S, et al. Increased vaccine efficacy against tuberculosis of recombinant mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin. J Clin Invest. [internet]. 2005;115(9):2472–2479. Available from: https://pubmed.ncbi.nlm.nih.gov/16110326
- Grode L, Ganoza CA, Brohm C, et al. Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial. Vaccine. 2013/01/08. 2013;31(9):1340–1348.
- Loxton AG, Knaul JK, Grode L, et al. Safety and immunogenicity of the recombinant mycobacterium bovis BCG vaccine VPM1002 in HIV-unexposed newborn infants in South Africa. Clin Vaccine Immunol. [internet]. 2017; 24(2):e00439–16. Available from: https://pubmed.ncbi.nlm.nih.gov/27974398
- Hoft DF, Blazevic A, Selimovic A, et al. Safety and immunogenicity of the recombinant BCG vaccine AERAS-422 in healthy BCG-naïve adults: a randomized, active-controlled, first-in-human Phase 1 trial. EBioMedicine. 2016/06/21 2016;7: 278–286.
- Tait DR, Hatherill M, Van Der Meeren O, et al. Final analysis of a trial of M72/AS01E vaccine to prevent tuberculosis. N Engl J Med. [internet]. 2019;381(25):2429–2439. Available from: https://doi.org/10.1056/NEJMoa1909953
- Darrah PA, Zeppa JJ, Maiello P, et al. Prevention of tuberculosis in macaques after intravenous BCG immunization. Nature. [internet]. 2020;577(7788):95–102. Available from: https://doi.org/10.1038/s41586-019-1817-8
- Chapman R, Chege G, Shephard E, et al. Recombinant mycobacterium bovis BCG as an HIV vaccine vector. Curr HIV Res. [internet]. 2010;8(4):282–298. Available from: https://pubmed.ncbi.nlm.nih.gov/20353397
- Honda M, Matsuo K, Nakasone T, et al. Protective immune responses induced by secretion of a chimeric soluble protein from a recombinant mycobacterium bovis bacillus Calmette-Guérin vector candidate vaccine for human immunodeficiency virus type 1 in small animals. Proc Natl Acad Sci USA. 1995;92(23):10693–10697. Available from: https://www.pnas.org/content/pnas/92/23/10693.full.pdf
- Matsuo K, Yamaguchi R, Yamazaki A, et al. Establishment of a foreign antigen secretion system in mycobacteria. Infect Immun. [internet]. 1990; 58(12):4049–4054. Available from: https://pubmed.ncbi.nlm.nih.gov/1701418
- Someya K, Cecilia D, Ami Y, et al. Vaccination of Rhesus macaques with recombinant mycobacterium bovis bacillus Calmette-Guerin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 Motif. J Virol. 2005/01/15. 2005;79(3):1452–1462.
- Méderlé I, Le Grand R, Vaslin B, et al. Mucosal administration of three recombinant mycobacterium bovis BCG-SIVmac251 strains to cynomolgus macaques induces rectal IgAs and boosts systemic cellular immune responses that are primed by intradermal vaccination. Vaccine. 2003/09/25. 2003;21(27–30):4153–4166.
- Kilpeläinen A, Maya-Hoyos M, Saubí N, et al. Advances and challenges in recombinant mycobacterium bovis BCG-based HIV vaccine development: lessons learned. Expert Rev Vaccines. [internet]. 2018; 17(11):1005–1020. Available from: https://doi.org/10.1080/14760584.2018.1534588
- Soto JA, Gálvez NMS, Rivera CA, et al. Recombinant BCG vaccines reduce pneumovirus-caused airway pathology by inducing protective humoral immunity. Front Immunol. 2018/12/26 2018;9: 2875.
- Abarca K, Rey-Jurado E, Muñoz-Durango N, et al. Safety and immunogenicity evaluation of recombinant BCG vaccine against respiratory syncytial virus in a randomized, double-blind, placebo-controlled phase I clinical trial. EClinicalMedicine [internet]. 2020; 27:100517. Available from: https://doi.org/10.1016/j.eclinm.2020.100517
- Stover CK, Bansal GP, Hanson MS, et al. Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine. J Exp Med. 1993/07/01. 1993;178(1):197–209.
- Langermann S, Palaszynski SR, Burlein JE, et al. Protective humoral response against pneumococcal infection in mice elicited by recombinant bacille Calmette-Guérin vaccines expressing pneumococcal surface protein A. J Exp Med. [internet]. 1994; 180(6):2277–2286. Available from: https://pubmed.ncbi.nlm.nih.gov/7964500
- Edelman R, Palmer K, Russ KG, et al. Safety and immunogenicity of recombinant Bacille Calmette-Guérin (rBCG) expressing Borrelia burgdorferi outer surface protein A (OspA) lipoprotein in adult volunteers: a candidate Lyme disease vaccine. Vaccine. [internet]. 1999;17(7–8):904–914. Available from: http://www.sciencedirect.com/science/article/pii/S0264410X9800276X
- Hanson MS, Lapcevich CV, Haun SL. Progress on development of the live BCG recombinant vaccine vehicle for combined vaccine delivery. Ann N Y Acad Sci. 1995/05/31. 1995;754(1 Combined Vacc):214–221.
- Da Silva Ramos Rocha A, Conceição FR, Grassmann AA, et al. B subunit of Escherichia coli heat-labile enterotoxin as adjuvant of humoral immune response in recombinant BCG vaccination. Can J Microbiol. [internet]. 2008; 54(8):677–686. Available from: https://doi.org/10.1139/W08-056
- Darrieux M, Goulart C, Briles D, et al. Current status and perspectives on protein-based pneumococcal vaccines. Crit Rev Microbiol. [internet]. 2015; 41(2):190–200. Available from: https://doi.org/10.3109/1040841X.2013.813902
- Biet F, Kremer L, Wolowczuk I, et al. Immune response induced by recombinant mycobacterium bovis BCG producing the cholera toxin B subunit. Infect Immun. [internet]. 2003; 71(5):2933–2937. Available from: https://pubmed.ncbi.nlm.nih.gov/12704173
- Mazzantini RP, Miyaji EN, Dias WO, et al. Adjuvant activity of mycobacterium bovis BCG expressing CRM197 on the immune response induced by BCG expressing tetanus toxin fragment C. Vaccine. 2004/01/27. 2004;22(5–6):740–746.
- Nascimento IP, Dias WO, Quintilio W, et al. Neonatal immunization with a single dose of recombinant BCG expressing subunit S1 from pertussis toxin induces complete protection against Bordetella pertussis intracerebral challenge. Microbes Infect. 2008/02/06. 2008;10(2):198–202.
- Matsumoto S, Yukitake H, Kanbara H, et al. Long-lasting protective immunity against rodent malaria parasite infection at the blood stage by recombinant BCG secreting merozoite surface protein-1. Vaccine. [internet]. 1999; 18(9–10):832–834. Available from: http://www.sciencedirect.com/science/article/pii/S0264410X99003266
- Arama C, Waseem S, Fernández C, et al. A recombinant bacille Calmette-Guérin construct expressing the plasmodium falciparum circumsporozoite protein enhances dendritic cell activation and primes for circumsporozoite-specific memory cells in BALB/c mice. Vaccine. 2011/10/11. 2012;30(37):5578–5584.
- Zheng C, Xie P, Chen Y. Immune response induced by recombinant BCG expressing merozoite surface antigen 2 from plasmodium falciparum. Vaccine. 2001/12/12. 2001;20(5–6):914–919.
- Varaldo PB, Leite LC, Dias WO, et al. Recombinant mycobacterium bovis BCG expressing the Sm14 antigen of schistosoma mansoni protects mice from cercarial challenge. Infect Immun. 2004/05/25. 2004;72(6):3336–3343.
- Baumgart KW, McKenzie KR, Radford AJ, et al. Immunogenicity and protection studies with recombinant mycobacteria and vaccinia vectors coexpressing the 18-kilodalton protein of mycobacterium leprae. Infect Immun. 1996;64(6):2274–2281. Available from: https://iai.asm.org/content/iai/64/6/2274
- Goulart C, Rodriguez D, Kanno AI, et al. Recombinant BCG expressing a PspA-PdT fusion protein protects mice against pneumococcal lethal challenge in a prime-boost strategy. Vaccine. 2017/03/01. 2017;35(13):1683–1691.
- Goulart C, Rodriguez D, Kanno AI, et al. A combination of recombinant mycobacterium bovis BCG strains expressing pneumococcal proteins induces cellular and humoral immune responses and protects against pneumococcal colonization and sepsis. Clin Vaccine Immunol. 2017/08/05. 2017;24(10):e00133–17.
- Morales A, Eidinger D, Bruce AW, Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. [internet]. 1976;116(2):180–182. Available from: http://www.sciencedirect.com/science/article/pii/S0022534717587376
- Pettenati C, Ingersoll MA. Mechanisms of BCG immunotherapy and its outlook for bladder cancer. Nat Rev Urol. [internet]. 2018;15:615–625. Available from: https://doi.org/10.1038/s41585-018-0055-4
- Zlotta AR, Fleshner NE, Jewett MA. The management of BCG failure in non-muscle-invasive bladder cancer: an update. Can Urol Assoc J [internet]. 1969; 3:S199–S205. Available from: https://cuaj.ca/index.php/journal/article/view/1196
- Brausi M, Oddens J, Sylvester R, et al. Side effects of Bacillus Calmette-Guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised Phase 3 study comparing one-third dose with full dose. Eur Urol. [internet]. 2014; 65(1):69–76. Available from: https://doi.org/10.1016/j.eururo.2013.07.021
- Begnini KR, Buss JH, Collares T, et al. Recombinant mycobacterium bovis BCG for immunotherapy in nonmuscle invasive bladder cancer. Appl Microbiol Biotechnol. [internet]. 2015; 99(9):3741–3754. Available from: https://doi.org/10.1007/s00253-015-6495-3
- Arnold J, De Boer EC, O’Donnell MA, et al. Immunotherapy of experimental bladder cancer with recombinant BCG expressing interferon-gamma. J Immunother. [internet]. 2004; 27(2):116–123. Available from: http://europepmc.org/abstract/MED/14770083
- Begnini KR, Rizzi C, Campos VF, et al. Auxotrophic recombinant mycobacterium bovis BCG overexpressing Ag85B enhances cytotoxicity on superficial bladder cancer cells in vitro. Appl Microbiol Biotechnol. [internet]. 2013; 97(4):1543–1552. Available from: https://doi.org/10.1007/s00253-012-4416-2
- Nieuwenhuizen NE, Kulkarni PS, Shaligram U, et al. The recombinant bacille Calmette–Guérin vaccine VPM1002: ready for clinical efficacy testing. Front Immunol. 2017;8:1147. Available from: https://www.frontiersin.org/article/10.3389/fimmu.2017.01147
- Andrade PM, Chade DC, Borra RC, et al. The therapeutic potential of recombinant BCG expressing the antigen S1PT in the intravesical treatment of bladder cancer. Urol Oncol Semin Orig Investig [internet]. 2010; 28:520–525. Available from: http://www.sciencedirect.com/science/article/pii/S1078143908003888
- Rodriguez D, Goulart C, Pagliarone AC, et al. In vitro evidence of human immune responsiveness shows the improved potential of a recombinant BCG strain for bladder cancer treatment. Front Immunol. 2019/07/13 2019;10: 1460.
- Duda RB, Yang H, Dooley DD, et al. Recombinant BCG therapy suppresses melanoma tumor growth. Ann Surg Oncol. [internet]. 1995; 2(6):542–549. Available from: https://doi.org/10.1007/BF02307089
- Fujimoto T, O’Donnell MA, Szilvasi A, et al. Bacillus Calmette-Guérin plus interleukin-2 and/or granulocyte/macrophage-colony-stimulating factor enhances immunocompetent cell production of interferon-γ, which inhibits B16F10 melanoma cell growth in vitro. Cancer Immunol Immunother. [internet]. 1996; 42(5):280–284. Available from: https://doi.org/10.1007/s002620050283
- Chung MA, Luo Y, O’Donnell M, et al. Development and preclinical evaluation of a bacillus Calmette-Guérin MUC1-based novel breast cancer. Vaccine. 2003;63:1280–1287. Available from: https://cancerres.aacrjournals.org/content/canres/63/6/1280.full.pdf
- Sun EL, Fan XD, Han RF, et al. Effect of recombinant hIFN-alpha-2b-BCG on mouse bladder tumor MB49 cells in vitro. Zhonghua Zhong Liu Za Zhi. 2010/06/01. 2010;32:244–248.
- Christ AP, Rodriguez D, Bortolatto J, et al. Enhancement of Th1 lung immunity induced by recombinant mycobacterium bovis bacillus Calmette-Guerin attenuates airway allergic disease. Am J Respir Cell Mol Biol. 2010;43:243–252. Available from: https://www.atsjournals.org/doi/abs/10.1165/rcmb.2009-0040OC
- Qu SY, Ou-Yang HF, He YL, et al. Der p 2 recombinant bacille Calmette-Guérin targets dendritic cells to inhibit allergic airway inflammation in a mouse model of asthma. Respiration. [internet]. 2013; 85(1):49–58. Available from: https://www.karger.com/DOI/10.1159/000340007
- Faustman DL, Wang L, Okubo Y, et al. Proof-of-concept, randomized, controlled clinical trial of bacillus-Calmette-Guerin for treatment of long-term Type 1 diabetes. PLoS One. [internet]. 2012; 7(8):e41756. Available from: https://doi.org/10.1371/journal.pone.0041756
- Moreira-Teixeira L, Tabone O, Graham CM, et al. Mouse transcriptome reveals potential signatures of protection and pathogenesis in human tuberculosis. Nat Immunol. [internet]. 2020; 21(4):464–476. Available from: https://doi.org/10.1038/s41590-020-0610-z
- Suscovich TJ, Fallon JK, Das J, et al. Mapping functional humoral correlates of protection against malaria challenge following RTS,S/AS01 vaccination. Sci Transl Med. [internet]. 2020; 12(553):eabb4757. Available from: http://stm.sciencemag.org/content/12/553/eabb4757.abstract
- Farias LP, Vitoriano-Souza J, Cardozo LE, et al. Systems biology analysis of the radiation-attenuated schistosome vaccine reveals a role for growth factors in protection and hemostasis inhibition in parasite survival [internet]. Front Immunol. 2021;51. Available from: https://www.frontiersin.org/article/10.3389/fimmu.2021.624191
- Cernuschi T, Malvolti S, Nickels E, et al. Bacillus Calmette-Guérin (BCG) vaccine: a global assessment of demand and supply balance. Vaccine [internet]. 2017/12/15. 2018; 36(4):498–506. Available from: https://pubmed.ncbi.nlm.nih.gov/29254839
- Chandran A, Williams K, Mendum T, et al. Development of a diagnostic compatible BCG vaccine against Bovine tuberculosis. Sci Rep. [internet]. 2019; 9(1):17791. Available from: https://doi.org/10.1038/s41598-019-54108-y
- Gupta R, Advancing new tools for infectious diseases. Science. [internet]. 2020; 370(6519): 913 LP – 914. Available from: http://science.sciencemag.org/content/370/6519/913.abstract